Inventor · disambiguated record
Gary R. Braslawsky
Also filed as: BRASLAWSKY GARY · BRASLAWSKY GARY R
10 granted patents·15 pending applications·2,050 citations·filing 1989–2010
94Inventor score
Files withBIOGEN IDEC INC14BRISTOL MYERS SQUIBB CO5BRASLAWSKY GARY R1BRISTOL MYERS SQUIBB1HANNA NABIL1
Top patents by PatentIndex Score
25 records- 0198US5122368AAnthracycline conjugates having a novel linker and methods for their productionBRISTOL MYERS SQUIBB CO·Filed 1989·Granted Jun 16, 1992·605 cites·12 claims
- 0297US5622929AThioether conjugatesBRISTOL MYERS SQUIBB CO·Filed 1992·Granted Apr 22, 1997·777 cites·52 claims
- 0397US5349066ABifunctional linking compounds, conjugates and methods for their productionBRISTOL MYERS SQUIBB CO·Filed 1992·Granted Sep 20, 1994·82 cites·8 claims
- 0495US5708146AThioether conjugatesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jan 13, 1998·178 cites·13 claims
- 0592US6897044B1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 1999·Granted May 24, 2005·133 cites·32 claims
- 0691US5137877ABifunctional linking compounds, conjugates and methods for their productionBRISTOL MYERS SQUIBB·Filed 1990·Granted Aug 11, 1992·113 cites·21 claims
- 0790US5606017AThioether conjugatesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Feb 25, 1997·82 cites·20 claims
- 0889US6998125B2Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisBIOGEN IDEC INC·Filed 2001·Granted Feb 14, 2006·25 cites·19 claims
- 0987US7319139B2TAG-72 specific CH2 domain deleted antibodiesBIOGEN IDEC INC·Filed 2002·Granted Jan 15, 2008·25 cites·22 claims
- 1085US7700097B2Purification and preferential synthesis of binding moleculesBIOGEN IDEC INC·Filed 2004·Granted Apr 20, 2010·30 cites·38 claims
- 1171US2008213260A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1271US2008213167A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1366US2006171950A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 1465US2008171056A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1563US2004137014A1Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisBIOGEN IDEC INC·Filed 2003·Application pending·0 cites
- 1663US2006286101A1Use of CD23 Antagonists for the Treatment of Neoplastic DisordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 1762US2008213168A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1861US2006286100A1Use of CD23 Antagonists for the Treatment of Neoplastic DisordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 1960US2003211107A1Use of CD23 antagonists for the treatment of neoplastic disordersFiled 2002·Application pending·0 cites
- 2056US2009022658A1Modified antibodies and methods of useBRASLAWSKY GARY R·Filed 2008·Application pending·0 cites
- 2155US2006153848A1Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisHANNA NABIL·Filed 2005·Application pending·0 cites
- 2254US2005118099A1Thiol-mediated drug attachment to targeting peptidesFiled 2004·Application pending·0 cites
- 2352US2005158828A1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 2447US2011020222A1Modified antibodies and methods of useBIOGEN IDEC INC·Filed 2010·Application pending·0 cites
- 2543US2002159996A1Use of CD23 antagonists for the treatment of neoplastic disordersFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gary R. Braslawsky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →